Liver transplantation for fatty liver disease

Journal of Digestive Diseases

Volumn 12, Issue 1, 2011, Pages 36-37

  Fung, John ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLITAZONE DERIVATIVE; TACROLIMUS;

ALCOHOL CONSUMPTION; ALCOHOL LIVER CIRRHOSIS; ALCOHOLIC FATTY LIVER; DIABETES MELLITUS; END STAGE LIVER DISEASE; FOLLOW UP; GRAFT FAILURE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LIVER FIBROSIS; LIVER FUNCTION TEST; LIVER TRANSPLANTATION; NONALCOHOLIC FATTY LIVER; OBESITY; PRIORITY JOURNAL; REVIEW;

FATTY LIVER; HUMANS; LIVER TRANSPLANTATION; MORBIDITY; POSTOPERATIVE COMPLICATIONS; RISK FACTORS;

EID: 79251578002     PISSN: 17512972     EISSN: 17512980     Source Type: Journal    
DOI: 10.1111/j.1751-2980.2010.00475.x     Document Type: Review

References (9)

1. Kim WR, Poterucha JJ, Porayko MK, Dickson ER, Steers JL, Wiesner RH. Recurrence of nonalcoholic steatohepatitis following liver transplantation. Transplantation 1996; 62: 1802-5.
2. Malik SM, Devera ME, Fontes P, Shaikh O, Sasatomi E, Ahmad J. Recurrent disease following liver transplantation for nonalcoholic steatohepatitis cirrhosis. Liver Transpl 2009; 15: 1843-51.
3. Yalamanchili K, Saadeh S, Klintmalm GB, Jennings LW, Davis GL. Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease. Liver Transpl 2010; 16: 431-9.
4. Dumortier J, Giostra E, Belbouab S etal. Non-alcoholic fatty liver disease in liver transplant recipients: another story of 'seed and soil'. Am J Gastroenterol 2010; 105: 613-20.
5. Bhagat V, Mindikoglu AL, Nudo CG, Schiff ER, Tzakis A, Regev A. Outcomes of liver transplantation in patients with cirrhosis due to nonalcoholic steatohepatitis versus patients with cirrhosis due to alcoholic liver disease. Liver Transpl 2009; 15: 1814-20.
6. Seo S, Maganti K, Khehra M etal. De novo nonalcoholic fatty liver disease after liver transplantation. Liver Transpl 2007; 13: 844-7.
7. Neuschwanter-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology 2010; 52: 774-88.
8. Belfort R, Harrison SA, Brown K etal. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006; 335: 2297-307.
9. Sanyla AJ, Chalasani N, Kowdley KV etal. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362: 1675-85.